Techtochrysin

Techtochrysin

SCHEMBL249043

COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 1.00
CYP3A4 P08684 5/20 1.00
ABCB1 P08183 4/20 1.00
CYP2C9 P11712 3/20 1.00
CYP2C19 P33261 3/20 1.00
ABCG2 Q9UNQ0 3/20 1.00
NPC1 O15118 3/20 1.00
TSHR P16473 1/20 1.00
MAOB P27338 3/20 0.82
FLT3 P36888 3/20 0.82
CYP19A1 P11511 2/20 0.82
IP6K2 Q9UHH9 2/20 0.82
MKNK2 Q9HBH9 1/20 0.82
CDK8 P49336 3/20 0.78
CCNC P24863 2/20 0.78
MEN1 O00255 4/20 0.74
ALDH1A1 P00352 4/20 0.74
KMT2A Q03164 4/20 0.74
SMN1; SMN2 Q16637 4/20 0.74
CYP1A1 P04798 4/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Techtochrysin SCHEMBL29494561 1.00 MAPT (1.00) MAPTCYP3A4ABCB1CYP2C9CYP2C19
Genkwanin SCHEMBL29445006 0.90 FLT3 (1.00) MAPTCYP3A4ABCB1CYP2C9CYP2C19
Genkwanin SCHEMBL866123 0.90 FLT3 (1.00) MAPTCYP3A4ABCB1CYP2C9CYP2C19
Apigenin Dimethylether SCHEMBL1176691 0.90 MAOB (1.00) MAPTCYP3A4ABCB1CYP2C9CYP2C19
Apigenin Dimethylether SCHEMBL29392759 0.90 MAOB (1.00) MAPTCYP3A4ABCB1CYP2C9CYP2C19
Genkwanin SCHEMBL2464219 0.89 CYP3A4 (0.80) MAPTCYP3A4ABCB1CYP2C9CYP2C19
SCHEMBL22729259 0.89 MAPT (0.81) MAPTCYP3A4ABCB1CYP2C9CYP2C19
Chrysin SCHEMBL28168227 0.89 MAPT (0.89) MAPTCYP3A4ABCB1CYP2C9CYP2C19
SCHEMBL28762810 0.89 MAPT (0.79) MAPTCYP3A4ABCB1CYP2C9CYP2C19
SCHEMBL28762731 0.88 CDK8 (1.00) MAPTCYP3A4ABCB1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115248-A1 METHOD FOR PRODUCING BLACK GINGER EXTRACT AND METHOD FOR PRODUCING COMPOSITION MARUZEN PHARM CO LTD (JP) 2026-04-30 US claimed
EP-4698662-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2026-02-25 EP claimed
US-20250367305-A1 ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-12-04 US claimed
WO-2024220449-A9 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2025-04-03 WO claimed
WO-2024220449-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2024-10-24 WO claimed
WO-2024177490-A1 ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME 서울대학교산학협력단 2024-08-29 WO claimed
CN-114867486-B Composition containing black ginger extract and composition for oral administration 丸善制药株式会社 2023-05-30 CN claimed
US-11596657-B2 Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2023-03-07 US claimed
US-20230021051-A1 Composition Containing Black Ginger Extract and Composition for Oral Administration MARUZEN PHARMACEUTICALS CO., LTD. (JP) 2023-01-19 US claimed
CN-115475157-A Intestinal barrier improving agent 株式会社资生堂 2022-12-16 CN claimed
CN-101423507-A Preparation of poplar antibacterial compounds and application thereof as bactericidal agent UNIV CHINA AGRICULTURAL (CN) 2009-05-06 CN claimed
EP-1067913-A4 COMPOSITIONS AND METHODS OF ADJUSTING STEROID HORMONE METABOLISM THROUGH FACILITATED ABSORPTION OF HYDROPHOBIC DIETARY COMPOUNDS BIORESPONSE LLC (US) 2009-03-11 EP claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
US-20040057908-A1 Oral compositions and use thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2004-03-25 US claimed
EP-1399119-A2 ORAL COMPOSITIONS AND USE THEREOF University of Rochester (US) 2004-03-24 EP claimed
WO-2002047615-A2 ORAL COMPOSITIONS AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2002-06-20 WO claimed
WO-2001003687-A2 METHOD AND COMPOSITIONS FOR INHIBITING BIOSYNTHESIS OR BIOACTIVITY OF ENDOGENOUS STEROID SEX HORMONES IN HUMANS CEDARS-SINAI MEDICAL CENTER (US) 2001-01-18 WO claimed
EP-1067913-A1 COMPOSITIONS AND METHODS OF ADJUSTING STEROID HORMONE METABOLISM THROUGH FACILITATED ABSORPTION OF HYDROPHOBIC DIETARY COMPOUNDS Bioresponse, L.L.C. (US) 2001-01-17 EP claimed
WO-1999049851-A1 COMPOSITIONS AND METHODS OF ADJUSTING STEROID HORMONE METABOLISM THROUGH FACILITATED ABSORPTION OF HYDROPHOBIC DIETARY COMPOUNDS BIORESPONSE, L.L.C. (US) 1999-10-07 WO claimed
US-4617293-A Flavonoid phosphate salts of aminoglycoside antibiotics MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1986-10-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115248-A1 METHOD FOR PRODUCING BLACK GINGER EXTRACT AND METHOD FOR PRODUCING COMPOSITION CYP4F8, CYP4F2, CYP4F11 MAPT 1398/4885CYP3A4 8/4885ABCB1 159/4885
US-20230021051-A1 Composition Containing Black Ginger Extract and Composition for Oral Administration CYP4F8, CYP4F2, CYP4F11 MAPT 842/4885CYP3A4 11/4885ABCB1 98/4885
US-20250367305-A1 ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME ALB, TNNC1, MYOF MAPT 629/4885CYP3A4 4025/4885ABCB1 3875/4885
US-20040057908-A1 Oral compositions and use thereof UGGT1, DPM1, B4GALT1 MAPT 1260/4885CYP3A4 269/4885ABCB1 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.